A watershed in ADC track investment has emerged, and “false competition+hematopoietic research and development” has become a new weather vane?
In particular, at a time when market expectations of the Federal Reserve's interest rate cut have declined sharply, and the global biomedical financing environment is far from improving, investors are more willing to look at companies with greater certainty.
Zhitong FinanceApr 26 04:18 ET
Top Gap Ups and Downs on Thursday: META, AZN, CAT and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
moomoo NewsApr 25 20:13 ET
Top Gap Ups and Downs on Wednesday: TSLA, TXN, BSX and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
moomoo NewsApr 24 19:42 ET
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)
TipRanksApr 16 20:21 ET
J&J Sets Guidance Below Consensus as MedTech Underperforms
Seeking AlphaApr 16 07:20 ET
Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug
Genmab (GMAB.CO) on Tuesday said the net sales for its multiple myeloma drug Darzalex rose year over year in the first quarter ended March. Net sales of Darzalex amounted to $2.69 billion in the first
MT NewswiresApr 16 07:19 ET
Express News | Genmab Reports DARZALEX Q1 Net Sales Of $2.692B
Moomoo 24/7Apr 16 06:42 ET
Genmab Announces Net Sales of DARZALEX (Daratumumab) for First Quarter of 2024
Company Announcement Net sales of DARZALEX in the first quarter of 2024 totaled USD 2,692 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen)COPENHAGEN, Denmar
GlobeNewswireApr 16 06:24 ET
Transactions in Connection With Share Buy-back Program Genmab
Company Announcement COPENHAGEN, Denmark; April 15, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion
GlobeNewswireApr 15 04:07 ET
Truist Financial Keeps Their Buy Rating on Genmab (GMAB)
TipRanksApr 9 07:35 ET
Genmab Advances Share Buy-back Program
TipRanksApr 8 14:28 ET
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), AbbVie (ABBV) and Immunome (IMNM)
TipRanksApr 8 03:50 ET
Express News | HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
Moomoo 24/7Apr 4 11:26 ET
Genmab Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/04/2024 65.56% HC Wainwright & Co. → $50 Reiterates Buy → Buy 03/27/2024 65.56% HC Wainwright & Co. $50
BenzingaApr 4 11:24 ET
Analysts' Top Healthcare Picks: Paragon 28 (FNA), Genmab (GMAB)
TipRanksApr 4 10:30 ET
Correction to Genmab Article
Antibody-drug conjugates, or ADCs, are manufactured antibodies that are administered to patients intravenously designed to deliver drugs to tumors. "Genmab Strengthens Oncology Portfolio With $1.8 Bln
Dow JonesApr 3 08:49 ET
Genmab Buys ProfoundBio for $1.8B, Adding to ADC Dealmaking Flurry
Yahoo FinanceApr 3 07:28 ET
Genmab (GMAB.US) invests $1.8 billion all-cash to acquire clinical-stage biotech company ProFoundBio
Genmab said on Wednesday it will acquire privately held clinical-stage biotech company ProFoundBio for $1.8 billion in full cash. The deal is expected to close in the first half of 2024.
Zhitong FinanceApr 3 04:45 ET
Express News | Genmab Acquires ProfoundBio To Strengthen Oncology Portfolio
Moomoo 24/7Apr 3 03:33 ET
Genmab Buys Ovarian Cancer Drug Developer for $1.8 Billion
BNN BloombergApr 3 02:55 ET
No Data
No Data